MAIA Biotechnology shares surge 12.04% intraday on Phase 3 trial success and FDA Fast Track for ateganosine.

MAIA Biotechnology surged 12.04% intraday following the release of its 2026 Shareholders’ Letter highlighting robust Phase 3 trial momentum for ateganosine, a first-in-class telomere-targeting agent in development for non-small cell lung cancer (NSCLC). The letter emphasized a high probability of technical success in both interim and full analysis of its Phase 3 trial, FDA Fast Track designation for third-line NSCLC treatment, and unprecedented clinical efficacy metrics, including a 38% overall response rate and 17.8-month median survival in third-line patients. The CEO underscored ateganosine’s potential to establish a new therapeutic category and address a $50 billion immunotherapy market, positioning the drug as a differentiated revenue opportunity outside existing checkpoint inhibitor competition. The news reinforced investor confidence in MAIA’s pipeline and regulatory pathway, directly driving the intraday rally.